Federal Contractor Misconduct Database (FCMD)
Remicade Anti-Competitive Pricing
The UK Competition and Markets Authority (CMA) issued a statement of objections to Merck subsidiary Merck Sharp & Dohme Limited (MSD) with regard to the pricing of its anti-inflammatory drug Remicade. The CMA provisionally found that MSD broke competition law by abusing its dominant position through a discount scheme for Remicade that was likely to restrict competition for biosimilar versions.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of CMA Provisional Decision